Reduced choroidal neovascular membrane formation in cyclooxygenase-2 null mice

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 2, 2011, Pages 701-707

  Rezaei, Kasra A ^a   Toma, Hassanain S ^a   Cai, Jiyang ^a   Penn, John S ^a,b,c   Sternberg, Paul ^a   Kim, Stephen J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Pharmacology ^*  (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; PTGS2 PROTEIN, MOUSE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOROID; CONTROLLED STUDY; FLUORESCENCE ANGIOGRAPHY; LASER COAGULATION; MOUSE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA; SCLERA; SUBRETINAL NEOVASCULARIZATION; WILD TYPE; ANIMAL; C57BL MOUSE; DISEASE MODEL; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CHOROID; CHOROIDAL NEOVASCULARIZATION; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; FLUORESCEIN ANGIOGRAPHY; INTERLEUKIN-1BETA; LASER COAGULATION; MICE; MICE, INBRED C57BL; RETINA; RETINAL PIGMENT EPITHELIUM; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79953275698     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6319     Document Type: Article

References (35)

1. Kedhar SR, Thorne JE, Wittenberg S, Dunn JP, Jabs DA. Multifocal choroiditis with panuveitis and punctate inner choroidopathy: comparison of clinical characteristics at presentation. Retina. 2007;27:1174-1179.
2. Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthal-mol. 2008;53:121-138.
3. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology. 1996;103:1241-1244.
4. Kim SJ, Toma HS. Inhibition of choroidal neovascularization by intravitreal ketorolac. Arch Ophthalmol. 2010;128:596-600.
5. Takahashi H, Yanagi Y, Tamaki Y, Uchida S, Muranaka K. COX-2-selective inhibitor, etodolac, suppresses choroidal neovasculariza-tion in a mice model. Biochem Biophys Res Commun. 2004;325: 461-466.
6. Yanni SE, Barnett JM, Clark ML, Penn JS. The role of PGE2 receptor EP4 in pathologic ocular angiogenesis. Invest Ophthalmol Vis Sci. 2009;50:5479-5486.
7. Chin MS, Nagineni CN, Hooper LC, Detrick B, Hooks JJ. Cycloox-ygenase-2 gene expression and regulation in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2001;42:2338-2346.
8. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55:108-133.
9. Maloney SC, Fernandes BF, Castiglione E, et al. Expression of cyclooxygenase-2 in choroidal neovascular membranes from age-related macular degeneration patients. Retina. 2009;29:176-180.
10. Hu W, Criswell MH, Ottlecz A, et al. Oral administration of lumira-coxib reduces choroidal neovascular membrane development in the rat laser-trauma model. Retina. 2005;25:1054-1064.
11. Sakamoto T, Soriana D, Nassaralla J, et al. Effect of intravitreal administration of indomethacin on experimental subretinal neo-vascularization in the subhuman primate. Arch Ophthalmol. 1995; 113:222-226.
12. Edelman JL, Castro MR. Quantitative image analysis of laser-induced choroidal neovascularization in rat. Exp Eye Res. 2000;71:523-533.
13. Toma HS, Barnett JM, Penn JS, Kim SJ. Improved assessment of laser-induced choroidal neovascularization. Microvasc Res. 2010;80:295-302.
14. Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods. 2000;243:243-255.
15. Carson RT, Vignali DA. Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. J Immunol Methods. 1999;227:41-52.
16. Rouzer CA, Marnett LJ. Cyclooxygenases: structural and functional insights. J Lipid Res. 2009;50:S29-S34.
17. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120.
18. Monnier Y, Zaric J, Ruegg C. Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back. Curr Drug Targets Inflamm Allergy. 2005;4:31-38.
19. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygen-ase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res. 2003;37:179-192.
20. Kim SJ, Toma HS, Barnett JM, Penn JS. Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. Exp Eye Res. 2010;91:537-543.
21. Takahashi K, Saishin Y, Saishin Y, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003;44: 409-415.
22. Wilson HL, Schwartz DM, Bhatt HR, et al. Statin and aspirin therapy are associated with decreased rates of choroidal neovasculariza-tion among patients with age-related macular degeneration. Am J Ophthalmol. 2004;137:615-624.
23. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolu-tionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225-260.
24. Ayalasomayajula SP, Amrite AC, Kompella UB. Inhibition of cyclo-oxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. Eur J Pharmacol. 2004;498: 275-278.
25. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007;2007:95-103.
26. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cycloox-ygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol. 2003;458:283-289.
27. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci. 2006;47:1149-1160.
28. Yanni SE, McCollum GW, Penn JS. Genetic deletion of COX-2 diminishes VEGF production in mouse retina Muller cells. Exp Eye Res. 2010;91:34-41.
29. Cheng T, Cao W, Wen R, Stenberg RH, LaVail MM. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Invest Ophthalmol Vis Sci. 1998;39:581-591.
30. Lee SH, Kim MH, Han HJ. Arachidonic acid potentiates hypoxia-induced VEGF expression in mouse embryonic stem cells: involvement of Notch, Wnt, and HIF-1alpha. Am J Physiol Cell Physiol. 2009;297:C207-C216.
31. Miller H, Miller B, Ishibashi T, Ryan SJ. Pathogenesis of laser-induced choroidal subretinal neovascularization. Invest Ophthal-mol Vis Sci. 1990;31:899-908.
32. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis. 2002;8:119-126.
33. Lopez PF, Grossniklaus HE, Lambert HM, et al. Pathologic features of surgically excised subretinal neovascular membranes in agerelated macular degeneration. Am J Ophthalmol. 1991;112:647-656.
34. Yu HG, Liu X, Kiss S, et al. Increased choroidal neovasculariza-tion following laser induction in mice lacking lysyl oxidase-like 1. Invest Ophthalmol Vis Sci. 2008;49:2599-2605.
35. Shinomiya S, Naraba H, Ueno A, et al. Regulation of TNFalpha and interleukin-10 production by prostaglandins I(2) and E(2): studies with prostaglandin receptor-deficient mice and prostaglandin E-re-ceptor subtype-selective synthetic agonists. Biochem Pharmacol. 2001;61:1153-1160.